2-chloro-5-(3-diethylamino-1-propoxy)nitrobenzene | 457600-90-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-5-(3-diethylamino-1-propoxy)nitrobenzene
• 英文别名: 3-(4-chloro-3-nitrophenoxy)-N,N-diethylpropan-1-amine
• CAS: 457600-90-7
• 化学式: C₁₃H₁₉ClN₂O₃
• 分子量: 286.758
• InChiKey: NIIYLHYALRCMJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-二乙氨基-1-丙醇 、 4-氯-3-硝基苯酚 、 甲基磺酰氯 在 三乙醇胺 、 potassium carbonate 作用下， 以 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-chloro-5-(3-diethylamino-1-propoxy)nitrobenzene
  参考文献：
  名称：

  Benzimidazole derivatives as therapeutic agents

  摘要：

  本发明提供了某些化合物、它们的制备方法、包含这些化合物的药物组合物以及它们在治疗人或动物疾病中的用途。本发明的化合物可用作高级糖基化终产物（AGEs）、S100/calgranulin/EN-RAGE、β-淀粉样蛋白和amphoterin等配体与高级糖基化终产物受体（RAGE）之间相互作用的调节剂，用于管理、治疗、控制或作为辅助治疗因RAGE引起的人类疾病。这些疾病或疾病状态包括急性和慢性炎症、糖尿病晚期并发症的发展，如增加的血管通透性、肾病、动脉粥样硬化和视网膜病变，阿尔茨海默病的发展、勃起功能障碍以及肿瘤侵袭和转移。

  公开号：

  US20030032663A1

文献信息

• Benzimidazole Derivatives as Therapeutic Agents
  申请人：Mjalli Adnan M.M.

  公开号：US20080119534A1

  公开（公告）日：2008-05-22

  This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

  本发明提供了某些化合物，其制备方法，包含这些化合物的制药组合物，以及它们在治疗人类或动物疾病中的应用。本发明的化合物可用作高级糖基化终产物受体（RAGE）及其配体（如高级糖基化终产物（AGEs），S100 / calgranulin / EN-RAGE，β-淀粉样蛋白和amphoterin）之间相互作用的调节剂，并用于管理，治疗，控制或作为辅助治疗人类因RAGE引起的疾病。这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，如增加的血管通透性，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍以及肿瘤侵袭和转移。
• BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS
  申请人：TransTech Pharma Inc.

  公开号：EP1387680A1

  公开（公告）日：2004-02-11
• US7087632B2
  申请人：——

  公开号：US7087632B2

  公开（公告）日：2006-08-08
• US7329684B2
  申请人：——

  公开号：US7329684B2

  公开（公告）日：2008-02-12
• [EN] BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS<br/>[FR] AGENTS THÉRAPEUTIQUES À BASE DE DÉRIVÉS BENZIMIDAZOLE
  申请人：TRANSTECH PHARMA INC

  公开号：WO2002069965A1

  公开（公告）日：2002-09-12

  This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ß-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.